The PrE0505 Study
For many years, the only approved systemic therapy for treating malignant pleural mesothelioma was cisplatin and pemetrexed combination therapy. The phase 2 DREAM study which involves durvalumab with chemotherapy, ended up resulting in a progression-free survival at six months. Additionally, combining the anti-PD-1 antibody nivolumab with the anti-CTLA-4 antibody ipilimumab improved survival for patients who […]
